Public Health and Medical Research, Charisma University, Grace Bay, Turks and Caicos Islands.
Global Clinical Scholars Research Training Program, Department of Postgraduate Medical Education, Harvard Medical School, Boston, Massachusetts, USA.
Metab Syndr Relat Disord. 2022 Mar;20(2):94-103. doi: 10.1089/met.2021.0042. Epub 2021 Dec 16.
The objective of this open-label pilot study was to investigate the efficacy of a very-low-carbohydrate ketogenic diet (VLCKD), known as Nic's Ketogenic Diet, for 140 days on cardiometabolic markers in healthy adults with mildly elevated low-density lipoprotein cholesterol (LDL-C). Study assessments were conducted at Day 0, 28, 56, 70, 84, 112, and 140, and weight and blood pressure (BP) were measured and fasting blood was collected for analysis of plasma lipids. A DEXA scan was performed and body mass index recorded on Day 0, 70, and 140. Blood glucose, inflammatory, and thyroid markers were measured on Day 0 and 140. Compliance was assessed using weekly 3-day food records and daily blood glucose and ketone monitoring. The results showed that body fat percentage decreased by 2.25% and 4.41% at Day 70 and 140, respectively ( ≤ 0.012). Significant reductions in android, gynoid, and android/gynoid fat ratio and increases in muscle mass occurred by Day 70 and 140. Total cholesterol, LDL-C, and high-density lipoprotein cholesterol were increased and systolic BP and glycated hemoglobin (HbA1c) were decreased at Day 140 ( < 0.05). Following this VLCKD for 140 days was found to be safe and was well tolerated. The VLCKD showed beneficial changes in body composition and cardiometabolic markers in eutrophic and overweight participants in a 140-day study suggesting a future role for this diet in populations at cardiovascular disease risk. Future research with larger sample size in a randomized double blind clinical trial is warranted to confirm these results. Clinical Trial Registration number: NCT04195594.
本开放性标签初步研究旨在探讨非常低碳水化合物生酮饮食(VLCKD),即尼克生酮饮食,对低密度脂蛋白胆固醇(LDL-C)轻度升高的健康成年人的 140 天的心脏代谢标志物的疗效。研究评估于第 0、28、56、70、84、112 和 140 天进行,测量体重和血压(BP),并采集空腹血样以分析血浆脂质。在第 0、70 和 140 天进行 DEXA 扫描并记录体重指数。在第 0 和 140 天测量血糖、炎症和甲状腺标志物。每周进行 3 天的食物记录,每天监测血糖和酮体,以评估依从性。结果显示,第 70 天和第 140 天体脂百分比分别下降了 2.25%和 4.41%( ≤ 0.012)。第 70 天和第 140 天出现了腹部、臀部和腹部/臀部脂肪比例的显著减少,以及肌肉量的增加。第 140 天总胆固醇、LDL-C 和高密度脂蛋白胆固醇增加,收缩压和糖化血红蛋白(HbA1c)降低( < 0.05)。在 140 天的研究中,这种非常低碳水化合物生酮饮食是安全且耐受良好的。这种生酮饮食在 140 天的研究中,对肥胖和超重参与者的身体成分和心脏代谢标志物产生了有益的变化,这表明该饮食在心血管疾病风险人群中有未来的应用价值。未来需要更大样本量的随机双盲临床试验来证实这些结果。临床试验注册号:NCT04195594。